D
ysregulation of blood glucose during critical illness has a negative impact on patient outcomes. Patients randomized to tight glycemic control, vs. permissive hyperglycemia, have improved intensive care unit (ICU) survival (1, 2) and long-term morbidity (3) (4) (5) . Similarly, ICU hypoglycemia is an independent risk factor for mortality in some studies (6, 7) , although its full consequences remain less clear (8) . In the ICU, it is difficult to avoid hyperglycemia without increasing the risk of hypoglycemia (9) . In striking a balance between hyper-and hypoglycemia, it is important to understand the associated morbidities, particularly the neuropsychiatric effects of glucose levels during critical illness. The brain is sensitive to both the metabolic restrictions of hypoglycemia (10, 11) and the detrimental effects of hyperglycemia (12) (13) (14) . In patients with diabetes mellitus, both hyperglycemia (15) and hypoglycemia (16, 17) are associated with a higher prevalence of depression. It is unclear whether similar associations hold for critically ill patients who experience wide variations in blood glucose during their ICU stay (18) and also have a high prevalence of depressive symptoms during their subsequent recovery (19 -21) . Among critically ill patients, those with acute lung injury (ALI) may be especially sensitive to the effects of blood glucose, given their high severity of illness, long ICU stay, and frequent long-term morbidity (12, 22, 23) . We hypothesized that such effects would be most pronounced during early recovery, when patients are no longer critically ill, but have not yet experienced many post-ICU events that could influence their psychiatric condition. Thus, we investigated the association of ICU blood glucose levels with symptoms of depression at 3 months after the diagnosis of ALI. d "Disabled" refers to patients who were unemployed due to health problems. "Other" includes students, homemakers, retired persons, and patients who were unemployed for nonhealth-related reasons;
e Six items describing pre-ICU functional status: bathing, dressing, toileting, transferring, continence, and feeding (28) . Proxies were asked when patients could not respond;
f Per EQ-5D quality of life survey (29) administered retrospectively to patients before hospital discharge; g This severity of illness score ranges from 0 (best) to 71 (worst) based on physiologic variables within 24 hrs of ICU admission, age, and chronic comorbidities (26) ; h This organ dysfunction score is recorded daily in the ICU and ranges from 0 (best) to 24 (worst) based on six major organ systems (27) .
MATERIALS AND METHODS
Study Population. The study population is drawn from the Improving Care of Acute Lung Injury Patients (ICAP) study, an ongoing prospective cohort study of the long-term physical and mental health outcomes of ALI survivors. Details of the study protocol have been published elsewhere (24) . In brief, the ICAP study prospectively collects clinical data for consecutive, mechanically ventilated patients with ALI, as defined by the American-European consensus conference (25) , at 12 ICUs in four hospitals in Baltimore, MD. To avoid inclusion of ALI patients with primary neurologic illness or trauma, patients in neurologic ICUs at the participating study site hospitals were not enrolled. The present analysis includes all participants who were diagnosed with ALI before January 7, 2007. Key exclusion criteria include 1) preexisting illness with a life expectancy of Ͻ6 months; 2) known cognitive impairment; 3) communication or language barrier; 4) transfer into study site ICU with preexisting ALI of Ͼ24 hrs duration; 5) Ͼ5 days of mechanical ventilation before ALI; 6) no fixed address; and 7) limitations in ICU care (e.g., no use of vasopressors). Patient demographics (age, gender, race), height, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II severity of illness score (26) are obtained upon admission to the study site ICU. Sequential Organ Failure Assessment score (27) , plus the dose, route and frequency of administration of selected medications (including insulin, corticosteroids, narcotics, and benzodiazepines) were collected daily after ALI diagnosis while patients were in the ICU. Antidepressant use was not measured. Comorbid conditions (e.g., diabetes mellitus) are abstracted from the medical record. Patients' functional status (independence in activities of daily living) (28), years of formal education, and employment status before hospitalization (including health-related employment restrictions) are collected by interview with the patient (or proxy, when unable to obtain patient response). Patients' mood symptoms before hospital admission were assessed retrospectively using the depression/anxiety dimension of the EQ-5D quality of life instrument (29) , modified to elicit patients' self-reported depression or anxiety immediately before the onset of the illness that caused hospital admission. In the present analysis, a response of "moderate" or "extreme" depression/anxiety (vs. "none") was considered a positive response for abnormal baseline mood symptoms. Age, ICU length of stay, and APACHE II and Sequential Organ Failure Assessment scores were modeled as continuous variables whereas all other continuous exposures were modeled as tertiles using clinically relevant thresholds closest to the 33rd and 67th percentile to characterize nonlinear associations and prevent undue influence from outlying observations.
Measurement of Blood Glucose in the ICU.
To evaluate hypoglycemia and hyperglycemia, we prospectively collected three distinct measures of blood glucose on a daily basis during eligible patients' ICU stay: 24-hr minimum, 24-hr maximum, and the average of values taken at 6 AM and 6 PM (Ϯ2 hrs). For each measure of blood glucose, we calculated patients' mean value over their entire ICU stay and stratified patients into tertiles (with thresholds rounded to the nearest multiple of 5 mg/dL). We also conducted an a priori secondary analysis of hypoglycemia, defined as any glucose value Ͻ60 mg/dL during patients' ICU stay (30) . Multiple episodes of hypoglycemia occurring on a single day were not separately recorded.
Measurement of Depression After Discharge. The primary outcome of this analysis was depression, measured at 3 months after ALI, as a continuous variable using the depression subscale of the Hospital Anxiety and Depression (HAD) instrument (31) . This subscale includes seven items with a total score ranging from 0 to 21. Higher scores indicate greater symptoms of depression. In a secondary analysis, we used a binary measure of depression as the outcome, defined a priori using a standard cut-off threshold for the HAD depression subscale of Ն8, with sensitivity analyses performed using the alternative higher threshold of Ն11 (31) . Although the HAD is a validated instrument, it does not permit a clinical diagnosis of depression, which would require clinical psychiatric interviews.
Statistical Analysis. We compared the distribution of all exposure variables across tertiles of mean ICU glucose using Fisher's exact test (categorical variables) and the global Ftest from analysis of variance (continuous variables). For each exposure variable, we calculated univariable p values for the association with mean depression score using linear leastsquares regression, and for the association with a positive depression screening test (HAD depression subscale score Ն8) using Fisher's exact test (categorical exposures) or logistic regression (continuous exposures). All exposure variables (Table 1) having a crude association with depression at p Յ 0.15 were analyzed in multivariable linear and logistic regression models. Missing data (which occurred only for education and baseline mood symptoms) were imputed using best-subset regression (32) . To avoid overestimating the magnitude of the association between exposure variables and depression (which had a high prevalence in our patient sample), we converted odds ratios from logistic regression into relative risks using the Zhang and Yu method (33) . Sequential removal of variables other than the primary exposure (to evaluate for model overfitting) and removal of patients with missing data (to evaluate the impact of imputation) did not materially change the association between the primary exposure and depression.
Potentially important statistical interactions of blood glucose with selected exposure variables were decided on an a priori basis and evaluated by including multiplicative terms in unadjusted linear regression models of mean depression score. Influence was evaluated using added-variable plots; the effect of outlier data values on regression coefficients was estimated using Dfbeta statistics; and collinearity was assessed using variance inflation factors (32, 34) . Goodness-of-fit was evaluated using the Hosmer-Lemeshow statistic for logistic models. All p values were two-sided, with statistical significance defined as p Ͻ 0.05. Analyses were performed using STATA version 9.2 (Stata Corp., College Station, TX).
The ICAP study was approved by the institutional review boards of all participating institutions.
RESULTS
Of 366 eligible patients, 191 (52%) survived hospitalization, of whom 135 were still alive and consented for follow-up at 3 months after ALI diagnosis (Fig. 1) . At follow-up, 15 patients (11%) were incapable of completing the depression questionnaire because of severe cognitive, physical, or other impairments, and 16 (12%) missed their appointment, resulting in complete depression surveys on 104 patients. Compared with the 104 included patients, these 31 3-month survivors not completing follow-up had a higher mean daily ICU maximum glucose (172 vs. 152 mg/dL, p ϭ 0.01) and a higher proportion experiencing hyperglycemia (71% vs. 50% with Ն1 measurement Ͼ210 mg/dL), but did not significantly differ with respect to mean daily ICU minimum glucose (108 vs. 104 mg/ dL, p ϭ 0.26) or proportion experiencing hypoglycemia (48% vs. 32% with Ն1 measurement Ͻ60 mg/dL, p ϭ 0.13). None of the included patients' medical records reported a history of "stroke," cerebrovascular accident, or transient ischemic attack. Patient exposures, including baseline characteristics, ICU course, and glucose measures were collected during 1717 ICU patient-days (Table 1) . When evaluating these exposures across tertiles of mean daily glucose, patients with higher glucose had significantly greater body mass index, higher prevalence of diabetes, and lower prevalence of mood symptoms at baseline; in the ICU, these patients received higher doses of insulin and steroids (Table 1) . Patients with lower mean glucose had a significantly lower mean daily minimum glucose, but did not have a significantly increased likelihood of experiencing at least one episode of hypoglycemia (Ͻ60 mg/dL). Hypoglycemia Ͻ60 mg/dL occurred in 33 (32%) patients, 12 (36%) of whom experienced hypoglycemia on Ͼ1 ICU day.
At follow-up, the mean HAD depression score was 5.5 (95% confidence interval [CI] 4.8 -6.3), and the prevalence of a positive screening test for depression was 28% (95% CI 19%-37%) using a HAD threshold of Ն8 points or 11% (4%-17%) using Ն11 points. The lowest tertile of mean daily minimum blood glucose (Ͻ100 mg/dL) was associated with worse depression outcomes (p Ͻ 0.01), while there was no association of depression screening results with mean or maximum blood glucose measures (Fig. 2) . Accordingly, all subsequent analyses of glucose and depression were restricted to measures of low blood glucose, with the primary exposure being mean daily minimum glucose Ͻ100 mg/dL (vs. Ն100 mg/dL). Sensitivity analyses conducted by varying the threshold for minimum glucose (in increments of 5 mg/dL) revealed that its association with a positive depression screening test was significant (p Ͻ 0.01) and similar in magnitude at all threshold values between 80 and 100 mg/dL.
In multivariable regression models, mean daily minimum glucose Ͻ100 mg/dL was associated with both HAD depression score (mean increase: 2.1, 95% CI 0.6 -3.7) ( Table 2 ) and prevalence of a positive depression screening test (relative risk [RR] for HAD Ն8: 2.6; 95% CI 1.2-4.2) ( Table 3 ). The occurrence of hypoglycemia (Ͻ60 mg/dL) had a similar association with depression score (mean increase: 2.0, 95% CI 0.5-3.5, p ϭ 0.007) and a positive depression screening test (RR for HAD Ն8: 3.6; 95% CI 1.8 -5.1, p ϭ 0.001). Other factors associated with both depression score ( Table 2) and a positive depression screen (Table 3) included morbid obesity (body mass index Ͼ40 kg/m 2 ) (RR 3.3, 95% CI 1.2-4.2) and symptoms of depression/anxiety before ICU admission (RR 3.9, 95% CI 1.5-6.5). Mean daily benzodiazepine dose Ͼ100 mg/day of midazolam-equivalent agent was associated with a positive depression screening test (RR 2.4, 95% CI 1.1-3.8; Table 3 ), but not with the mean HAD depression score. The only variables that were not significantly associated with a positive depression screening test under a more stringent significance level of p Ͻ 0.025 (i.e., a Bonferroni correction for two different depression outcomes) were body mass index and benzodiazepine use.
The associations of minimum glucose and hypoglycemia with the HAD depression score demonstrated a significant (p ϭ 0.01) interaction (Fig. 3) . Patients with both low minimum glucose and hypoglycemia had significantly elevated depression scores (mean increase 4.0, 95% CI 2.4 -5.7) and prevalence (RR 3.9, 95% CI 1.9 -7.7). Diabetes status, baseline symptoms of anxiety/depression, ICU length of stay, and benzodiazepine dose did not demonstrate a significant interaction with minimum glucose on depression score (p Ն 0.3 for each comparison). Table 1 which were associated (at p Ͻ 0.15) with mean depression score. Categories (as presented in Table 1 ) were collapsed to create a binary variable when a factor's association with depression did not vary across the additional categories;
b Measured by the seven-item Hospital Anxiety and Depression (HAD) instrument's depression subscale, a continuous measure ranging from 0 to 21 with predefined thresholds for depression screening of Ն8 and Ն11 (31) . Results are presented as the increase in mean HAD depression score, comparing patients with the factor of interest with those without that factor, using a linear regression model;
c Per EQ-5D quality of life survey (29) administered retrospectively to patients before hospital discharge. Table 1 which were associated (at p Ͻ 0.15) with presence of a positive depression screening test, defined as a score of Ն8 on the Hospital Anxiety and Depression depression subscale. Categories (as presented in Table 1 ) were collapsed to create a binary variable when a factor's association with depression did not vary across the additional categories; b Univariable p values were calculated using Fisher's exact test. Multivariable relative risks were calculated using the Zhang and Yu (33) correction to odds ratios obtained from a logistic regression model;
c Per EQ-5D quality of life survey (29) administered retrospectively to patients before hospital discharge.
DISCUSSION
In this prospective observational study, measures of low blood glucose in the ICU were significantly associated with depressive symptoms at 3 months after ALI. Mean daily minimum glucose Ͻ100 mg/dL was independently associated with a 2.6-fold increased risk of depression (HAD depression score Ն8), and documented hypoglycemia (Ͻ60 mg/dL) was associated with a 3.6-fold increased risk. Patients with both low minimum glucose and hypoglycemia experienced the greatest risk for depressive symptoms. These findings suggest that hypoglycemia during critical illness is associated with depression during ALI survivors' early recovery.
The 28% prevalence of a positive depression screening test at 3 months after ALI in this study is similar to prevalence rates of 25% to 32% reported in other populations of mechanically ventilated patients (35) (36) (37) , and substantially higher than the 8% prevalence of depression (using HAD depression score Ն8) in a general adult population (38) . Similarly, when defining hypoglycemia as Ͻ40 mg/ dL, as done in a large randomized trial of tight glycemic control in a medical ICU (6), our rates (6% in patients not on insulin infusion protocol, 24% on protocol) were very similar to that trial (4%, 25%). Because of our limited number of patients with hypoglycemia Ͻ40 mg/dL (n ϭ 9), we did not analyze these patients separately. However, these patients had similar levels of depressive symptoms, whether measured by mean HAD score or prevalence of scores Ն8, to the 24 hypoglycemic patients with glucose values between 41 and 59 mg/dL (p Ͼ 0.7 for comparison of each outcome).
Our findings suggest that depressive symptoms are more strongly associated with a combination of documented hypoglycemia and low daily minimum glucose than with either factor alone. Specifically, documented hypoglycemia may be most strongly associated with depressive symptoms in patients whose daily minimum values have also been low during their ICU stay. Low minimum glucose may reflect additional episodes of undetected hypoglycemia, especially because commonly used capillary blood glucose measurements may overestimate serum values in ICU patients (39, 40) . Thus, intensified glucose monitoring may be justified for patients at risk for hypoglycemia, such as those with diabetes mellitus, changing nutritional intake, continuous renal replacement therapy, sepsis, and insulin infusion protocols for tight glycemic control (7, 11, 30, 41, 42) .
To our knowledge, this is the first study to investigate the association of ICU blood glucose with depression after critical illness. Follow-up from the van den Berghe et al. (4) trial suggested that ICU hypoglycemia (Ͻ40 mg/dL) was not associated with persistently altered neurologic status, epilepsy, and coma at hospital discharge or with diminished performance status at 4 yrs (2). However, an association with psychiatric symptoms was not reported.
Our results add to the growing body of evidence that patients' condition and management while in the ICU may have an important impact on their outcomes after hospital discharge. Previous studies have found associations of ICU hypoxia with neurocognitive impairments at hospital discharge (12) and duration of sedative administration with postdischarge depression (43) . This latter finding is corroborated by our observation that mean daily ICU benzodiazepine dose was significantly associated with a positive depression screening test, independent of patients' baseline depression/anxiety status. Future studies of critically ill patients should consider measuring postdischarge neuropsychiatric outcomes in survivors to further explore these relationships.
This research has a number of potential limitations. First, as an observational study, we cannot infer a cause-effect relationship between ICU glucose and depression. Glucose may be a physiologic marker of other processes contributing to postdischarge depression, rather than a causal factor itself. Further research is required to elucidate a causal mechanism. However, we did measure and adjust for relevant potential confounders, including other risk factors for depression [e.g., baseline mood symptoms, baseline functional status (44) , benzodiazepine use (43) ]. Second, our hospital mortality rate was high (48%), but comparable with other observational studies of ALI patients (45) (46) (47) and lower than the mean predicted mortality rate (55%, 95% CI 52%-59%) based on our patients' high APACHE II severity of illness scores (26) . Third, we measured mood symp- Figure 3 . Effect of documented hypoglycemia and mean daily minimum ICU blood glucose on depression during early recovery from acute lung injury. Bars show the proportion of patients with depressive symptoms, according to severity (gray, depression score Ն8; black, depression score Ն11). Lines show mean depression scores with 95% confidence intervals. Hypoglycemia is defined as a documented blood glucose Ͻ60 mg/dL during ICU stay. Relative risks were calculated for a depression score Ն8. *p Ͻ 0.01 for all pairwise comparisons with other groups; **p Յ 0.001 for all pairwise comparisons with other groups. HAD, Hospital Anxiety and Depression; ICU, intensive care unit.
toms at baseline using the single-item EQ-5D depression/anxiety dimension, and at follow-up with the seven-item HAD depression subscale. Although both instruments have been independently validated, they do not constitute a clinical diagnosis of depression, suggesting a need for further studies employing clinical assessments of depression in ICU survivors. Fourth, we limited our study to depressive symptoms and cannot comment on the association of ICU glucose levels with other potentially important outcomes, including neuromuscular dysfunction (48) and posttraumatic stress (19, 21) . Fifth, although patients with known cognitive impairment before hospitalization were excluded from the study, we did not collect detailed data on cognitive impairment or antidepressant use at follow-up; this may have affected our 3-month assessments of patients' depression symptoms. Although patients with lower post-ICU cognitive function might be expected to have worse depression scale scores, one prior study (12) found no association between cognitive impairment and symptoms of depression in ALI survivors. Finally, we measured only daily minimum, maximum, and 6 AM/6 PM glucose values between ALI diagnosis and ICU discharge. Thus, we could not fully capture all relevant hypoglycemic events (e.g., repeat events in one day, prolonged events, or those occurring either before ALI diagnosis or after ICU discharge) that may have contributed to postdischarge depressive symptoms. However, our primary exposure (mean minimum daily glucose) was prospectively collected and available for 1712 (99.7%) of 1717 eligible patient-days, and any under-recognition of low blood glucose would likely bias our results toward the null hypothesis of no association.
CONCLUSIONS
This observational study of 104 ALI survivors over 1,717 days of ICU care suggests that ICU hypoglycemia is strongly associated with symptoms of depression during patients' early recovery from critical illness. Other factors associated with post-ALI depressive symptoms include baseline mood, morbid obesity, and ICU benzodiazepine dose. These findings warrant increased glucose monitoring for ICU patients at risk for hypoglycemia, and further research on how patient and ICU management factors contribute to post-ICU depression.
